Acanthoic acid
Acanthoic acid (NP1302) is an orally active pimarane-type diterpenoid. Acanthoic acid is isolated from the root bark of Araliaceae family plant Eleutherococcus senticosus (Siberian ginseng). Acanthoic acid activates LXR and FXR. Acanthoic acid activates the AMPK-LKB1, SIRT1, and p38 MAPK signaling pathways and increases the phosphorylation level of ACC. Acanthoic acid downregulates the expression of SREBP-1, CYP2E1, HIF-1α, and PPARγ, and upregulates the expression of PPARα. Acanthoic acid induces Apoptosis by activating Caspase-3, promoting PARP cleavage, and downregulating Bcl-xL. Acanthoic acid exhibits antioxidant, anti-fibrotic, and hepatoprotective effects. It reduces lipid accumulation and lipogenesis. Acanthoic acid is used in studies on non-alcoholic fatty liver disease, alcoholic liver disease, acute promyelocytic leukemia, and Acetaminophen-induced hepatotoxicity.
For research use only. We do not sell to patients.
- CAS No.: 119290-87-8
- Formula: C20H30O2
- Molecular Weight:302.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
SIRT1 |
CYP2E1 |
HIF-1α |
PPARγ |
PPARα |
Caspase 3 |
Bcl-xL |
In Vitro
Acanthoic acid (5 μM; 3 days) modulates FXR, LXRα, LXRβ, and SREBP-1 protein levels in PA-stimulated AML-12 hepatocytes, consistent with activation of FXR/LXR signaling and downregulation of SREBP-1[1].
Acanthoic acid (5 μM; 3 days) modulates FXR, LXRα, LXRβ, SREBP-1, and SREBP-1 target gene mRNA levels in PA-stimulated AML-12 hepatocytes, consistent with activation of FXR/LXR signaling and downregulation of lipogenic gene expression[1].
Acanthoic acid (5 μM; 3 days) increases FXR fluorescence intensity in PA-stimulated AML-12 hepatocytes, consistent with activation of FXR signaling[1].
Acanthoic acid (5 μM; 3 days) increases LXRβ fluorescence intensity in PA-stimulated AML-12 hepatocytes, consistent with activation of LXR signaling[1].
In EtOH/LPS-stimulated AML-12 mouse hepatocytes, acanthoic acid (5-20 µM; 2 h pretreatment + 48 h co-treatment) reduces lipid deposition and inflammatory cytokine production while activating the Sirt1/LKB1/AMPK/ACC and LXRs signaling pathways[2].
Acanthoic acid (50-200 μM; 0-24 h) inhibits HL-60 human promyelocytic leukaemia cell proliferation in a dose- and time-dependent manner, with 86% growth reduction at 150 μM after 24 h[3].
Acanthoic acid (150 μM; 3 h) activates ERK and p38 MAPK phosphorylation in HL-60 human promyelocytic leukaemia cells after 3 h of treatment at 150 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:AML-12 mouse hepatocytes
-
Concentration:5 μM
-
Incubation Time:3 days
-
Result:Decreased the elevated protein expression of SREBP-1 in PA-stimulated AML-12 cells.
Ameliorated the PA-induced reduction of FXR, LXRα, and LXRβ protein levels.
Showed effects consistent with the LXR agonist GW3965 in increasing LXRα, LXRβ, and FXR protein levels and suppressing SREBP-1 protein expression.
-
Cell Line:AML-12 mouse hepatocytes
-
Concentration:5 μM
-
Incubation Time:3 days
-
Result:Decreased the elevated mRNA expression of SREBP-1 and its target genes Fasn, Scd, and Acly in PA-stimulated AML-12 cells.
Ameliorated the PA-induced reduction of FXR, LXRα, and LXRβ at the mRNA level.
Showed effects consistent with the LXR agonist GW3965 in increasing FXR, LXRα, and LXRβ mRNA levels and suppressing SREBP-1 and its target gene mRNA expression.
-
Cell Line:AML-12 mouse hepatocytes
-
Concentration:5 μM
-
Incubation Time:3 days
-
Result:Enhanced the FXR fluorescence intensity that had been reduced by PA in AML-12 cells.\nEnhanced the LXRβ fluorescence intensity that had been reduced by PA in AML-12 cells.
Showed effects consistent with the LXR agonist GW3965 in increasing LXRβ fluorescence intensity.
-
Cell Line:HL-60 human promyelocytic leukaemia cells
-
Concentration:50-200 μM (dose-response); 150 μM (time-course)
-
Incubation Time:24 h (dose-response); 0-24 h (time-course)
-
Result:Reduced HL-60 cell proliferation in a dose- and time-dependent manner.
Exposure to 150 μM for 24 h reduced HL-60 cell proliferation by 86%.
-
Cell Line:HL-60 human promyelocytic leukaemia cells
-
Concentration:150 μM
-
Incubation Time:3 h
-
Result:Had little effect on JNK phosphorylation.
Dramatically increased phosphorylation of ERK and p38 MAPK compared to untreated cells.
Did not affect total non-phosphorylated p38 MAPK expression.
In Vivo
Acanthoic acid (20-40 mg/kg; p.o.; once daily; 14 days) attenuates acute alcohol-induced liver lipid deposition and inflammation in mice by activating the LKB1/Sirt1/AMPK/ACC and LXR pathways[2].
Acanthoic acid (50-100 mg/kg; p.o.; once daily; 3 consecutive days) dose-dependently attenuates Acetaminophen (HY-66005)-induced hepatic injury in mice, with 100 mg/kg oral treatment restoring hepatic antioxidant enzyme activities and reducing serum transaminase levels, lipid peroxidation, proinflammatory cytokine levels, and apoptotic/hypoxia marker expression[4].
Acanthoic acid (50-100 mg/kg; p.o.; once daily; 3 consecutive days) dose-dependently increases 24 h survival rate in mice challenged with a lethal dose of Acetaminophen, reaching 74% survival at 100 mg/kg oral pretreatment[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male; 6-week old; 22-24 g; high-fat diet induced)[1]
-
Dosage:20 mg/kg; 40 mg/kg
-
Administration:p.o.; daily; 12 weeks
-
Result:Decreased body weight gain and liver index induced by the high-fat diet.
Reduced serum transaminase (ALT, AST) levels.
Lowered both serum and hepatic triglyceride levels.
Reversed liver enlargement, surface fat accumulation, and softened liver texture.
Ameliorated diffuse hepatic fatty degeneration, inflammatory cell infiltration, and hepatocyte degeneration.
Reduced lipid droplet accumulation in the liver as shown by H&E, Oil Red O, and Nile red staining.
Progressively decreased the protein and mRNA expression of SREBP1 and its target genes Fasn, Scd, and Acly.
Up-regulated PPARα expression.
Down-regulated PPARγ expression in the liver.
Significantly decreased the protein and mRNA expression of hepatic fibrosis markers α-SMA, collagen І, and TIMP-1.
Significantly increased the protein and mRNA expression of LXRα, LXRβ, and FXR.
Enhanced the phosphorylation of AMPKα.
Reduced the phosphorylation of LKB1.
Increased SIRT1 protein expression in the liver.
Showed no significant effects on the above parameters in normal diet-fed mice at 40 mg/kg single administration.
-
Animal Model:C57BL/6 (male; 6-week-old; body weight 18-22 g; acute binge model induced by three doses of ethanol 5 g/kg by gavage within 24 h at 12 h intervals)[2]
-
Dosage:20 mg/kg; 40 mg/kg
-
Administration:p.o.; once daily; 14 consecutive days
-
Result:Suppressed acute ethanol-induced increases in serum ALT, AST, LDH, and ALP levels.
Reversed elevated serum and hepatic triglyceride levels.
Reduced massive hepatic steatosis and diminished red-stained lipid droplet accumulation in liver tissue.
Significantly reversed ethanol-induced upregulation of SREBP-1 at both protein and mRNA levels.
Decreased SREBP-1 immunohistochemical positive staining.
At 40 mg/kg, significantly suppressed ethanol-induced CYP2E1 protein elevation.
Markedly inhibited ethanol-induced increases in IL-1β and caspase-1 at both mRNA and protein levels.
Decreased F4/80 expression in liver tissue.
Increased Sirt1 protein expression in both cytoplasm and nucleus.
Elevated phosphorylation levels of LKB1, AMPKα, AMPKβ, and ACC that were reduced by ethanol.
Reversed ethanol-induced decreases in LXRα and LXRβ mRNA levels.
Restored PPARα protein expression.
Decreased ethanol-elevated PPARγ protein expression.
-
Animal Model:C57BL/6 (male; 6-7 weeks old; 21-24 g; acetaminophen-induced sub-lethal hepatic toxicity via 300 mg/kg acetaminophen i.p. injection)[4]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:p.o.; once daily; 3 consecutive days
-
Result:Reduced serum ALT activity to 138 IU/L at 50 mg/kg and 102 IU/L at 100 mg/kg.
Reduced serum AST activity to 119 IU/L at 50 mg/kg and 94 IU/L at 100 mg/kg.
Reduced serum TNF-α level to 80.0 pg/mL at 50 mg/kg and 65.9 pg/mL at 100 mg/kg.
Reduced liver MDA level to 7.24 nmol/mg prot at 50 mg/kg and 5.05 nmol/mg prot at 100 mg/kg.
Increased liver GSH level to 417.25 mg/g prot at 50 mg/kg and 431.19 mg/g prot at 100 mg/kg.
Increased liver SOD activity to 69.22 U/mg prot at 50 mg/kg and 73.46 U/mg prot at 100 mg/kg.
Increased liver CAT activity to 45.71 U/mg prot at 50 mg/kg and 52.92 U/mg prot at 100 mg/kg.
Increased liver GSH-Px activity to 783.39 U/L at 50 mg/kg and 847.13 U/L at 100 mg/kg.
Reduced caspase-3 expression in liver tissue at both doses.
Reduced HIF-1α expression in liver tissue in a dose-dependent manner.
-
Animal Model:C57BL/6 (male; 6-7 weeks old; 21-24 g; acetaminophen-induced lethal hepatic toxicity via 500 mg/kg APAP i.p. injection)[4]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:p.o.; once daily; 3 consecutive days (final dose 2 h before APAP challenge)
-
Result:Increased 24 h survival rate to 52% at 50 mg/kg after lethal APAP challenge.
Increased 24 h survival rate to 74% at 100 mg/kg after lethal APAP challenge.
Chemical Information
-
CAS No. 119290-87-8
-
Molecular Weight 302.45
-
Formula C20H30O2
-
SMILES
C[C@]12[C@@](CC[C@]3([H])C2=CC[C@@](C)(C3)C=C)([H])[C@@](C)(CCC1)C(O)=O
-
Synonyms
NP1302
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
3T3-L1 preadipocyte-to-adipocyte differentiation
3T3-L1 preadipocytes are induced to differentiate after growth arrest using adipogenic media containing insulin, dexamethasone, and IBMX; differentiation is assessed by lipid-droplet accumulation, triglyceride increase, Oil Red O staining, and adipocyte-marker induction such as PPARγ and C/EBPα.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Hepatotoxicity Study
This protocol evaluates hepatotoxicity using complementary in vivo mouse APAP acute liver injury and in vitro hepatocyte-based cytotoxicity readouts. In vivo APAP injury is assessed by serum ALT/AST, liver histology, hepatic glutathione, protein adducts, necrosis, inflammation, and regeneration-related endpoints. In vitro hepatotoxicity is assessed by loss of viability, leakage of ALT/AST/LDH, oxidative-stress markers, mitochondrial function, nuclear morphology, intracellular calcium, and high-content imaging endpoints.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Lipid Droplets: Oil Red O/Sudan Dye Lipid Staining
Lipid droplets are intracellular organelles with a neutral-lipid core that stores triacylglycerols and sterol esters, and Oil Red O or Sudan dyes detect these hydrophobic lipid deposits by partitioning into retained lipids in fresh or frozen specimens. Oil Red O stains neutral triglycerides and lipids in frozen tissue sections or air-dried cytologic preparations, while Sudan Black B has also been used as a histochemical fat stain for lipid-rich tissue structures.
Purity & Documentation
References
[3]. Kim KN, et al. Acanthoic acid induces cell apoptosis through activation of the p38 MAPK pathway in HL-60 human promyelocytic leukaemia. Food chemistry. 2012 Dec 01;135(3):2112-7. [Content Brief]
[4]. Wu YL, et al. Acanthoic acid, a diterpene in Acanthopanax koreanum, protects acetaminophen-induced hepatic toxicity in mice. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2010 May;17(6):475-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Acanthoic acid
- 119290-87-8
- NP1302
- NP 1302
- NP-1302
- LXR
- FXR
- AMPK
- Sirtuin
- p38 MAPK
- Acetyl-CoA Carboxylase
- Cytochrome P450
- HIF/HIF Prolyl-Hydroxylase
- PPAR
- Caspase
- PARP
- Bcl-2 Family
- Apoptosis
- nonalcoholic fatty liver disease
- AML-12 hepatocytes
- SIRT1
- Acanthopanax koreanum
- acetaminophen-induced hepatic toxicity
- HL-60 human promyelocytic leukaemia cells
- AMPK-LKB1
- Inhibitor
- inhibitor
- inhibit